A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Phase 1/2 Active not recruiting 24 enrolled Genentech, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

Timeline

Start: 2025-03-31
Primary completion: 2026-07-13
Completion: 2026-08-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vixarelimab	Monoclonal antibody	—	Subcutaneous

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Summary

Timeline

Drugs

Indications